[1]Wang MJ, Wang YT, Feng XS, et al.Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center. Int J Infect Dis, 2017, 65: 15-21.
[2］Papatheodoridis GV, Chan HL, Hansen BE, et al.Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol, 2015, 62: 956-967.
[3］Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018, 29: 238-255.
[4］Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res, 2015, 45:123-127.
[5］陈万青, 崔富强, 樊春笋, 等.中国肝癌一级预防专家共识(2018).临床肝胆病杂志, 2018, 34:2090-2097.
[6］Lok AS, McMahon BJ, Brown RS, et al.Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis.Hepatology, 2016, 63:284-306.
[7］Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology, 2014, 147:143-151.
[8］Tan YF, Zhang XY, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in mainland China.Cancer Epidemiol Biomarkers Prev, 2019, 28: 2038-2046.
[9］Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66: 335-343.
[10］Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019, 70: 361-370.
[11］Cheung KS, Seto WK, Wong DK, et al. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.J Viral Hepat, 2017, 24: 654-661.
[12］Wong GL, Chan HL, Tse YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol, 2018, 69:793-802.
[13］Loglio A, Lavarone M, Viganò M, et al. Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.Liver Int, 2019, 39: 1964-1974.
[14］Choi J, Kim GA, Han S, et al. Longitudinal assessment of three serum biomarkers to detect very early stage hepatocellular carcinoma. Hepatology, 2019, 69:1983-1994.
[15］Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.J Hepatol, 2009, 50: 80-88.
[16］Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.J Clin Oncol, 2010, 28: 1660-1665.
[17］Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.Lancet Oncol, 2011, 12: 568-574.
[18］Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B .J Hepatol, 2014, 60: 339-345.
[19］Jung KS, Kim SU, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.Hepatology, 2015, 62: 1757-1766.
[20］Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol, 2016, 64: 800-806.
[21］刘梦晓. 瞬时弹性成像技术、甲胎蛋白联合FIB-4指数对乙型肝炎相关性肝细胞癌预测价值的临床研究.吉林大学, 2019.
[22］原发性肝癌诊疗规范(2019年版).临床肝胆病杂志, 2020, 36:277-292.
[23］Kim GA, Seock CH, Park JW, et al. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment.Liver Int, 2015, 35:232-239.
[24］Wong GL, Chan HL, Tse YK, et al.On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.Hepatology, 2014, 59:986-995.
[25］Shim JJ, Kim JW, Lee CK, et al. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B.J Gastroenterol Hepatol, 2014, 29:1699-1705.
[26］Poté N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.J Hepatol, 2015, 62: 848-854.
[27］Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.Scand J Gastroenterol, 2016, 51:344-353.
[28］Ning S, Liu H, Gao B et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma.Oncol Lett, 2019, 18: 3381-3387.
[29］缑文斌, 田素升, 李长风.P53和Hsp70在肝癌、肝硬化及肝血管瘤的表达及意义.肝脏, 2018, 23:410-413.
[30］Fu Y, Xu X, Huang D, et al.Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: an official, large-scale, and Multicenter Clinical Trial. EBioMedicine, 2017, 24: 56-63.
[31］梁靖晨, 刘军杰.新型肝癌生物标志物的研究进展.医学综述, 2019, 25:2143-2148.
[32］Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients.Clin Gastroenterol Hepatol, 2016, 14:875-886.
[33］Yang T, Xing H, Wang GQ, et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B.Clin Chem, 2019, 65: 1543-1553.
[34］陈松海, 纪冬, 胡志军, 等.瞬时弹性成像联合甲胎蛋白对肝细胞癌的早期预警价值.肝脏, 2019, 24:20-23. |
